Megalencephalic Leukoencephalopathy: Insights Into Pathophysiology and Perspectives for Therapy
Open Access
- 22 January 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
Abstract
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare genetic disorder belonging to the group of vacuolating leukodystrophies. It is characterized by megalencephaly, loss of motor functions, epilepsy, and mild mental decline. In brain biopsies of MLC patients, vacuoles were observed in myelin and in astrocytes surrounding blood vessels. It is mainly caused by recessive mutations in MLC1 and HEPACAM (also called GLIALCAM) genes. These disease variants are called MLC1 and MLC2A with both types of patients sharing the same clinical phenotype. Besides, dominant mutations in HEPACAM were also identified in a subtype of MLC patients (MLC2B) with a remitting phenotype. MLC1 and GlialCAM proteins form a complex mainly expressed in brain astrocytes at the gliovascular interface and in Bergmann glia at the cerebellum. Both proteins regulate several ion channels and transporters involved in the control of ion and water fluxes in glial cells, either directly influencing their location and function, or indirectly regulating associated signal transduction pathways. However, the MLC1/GLIALCAM complex function and the related pathological mechanisms leading to MLC are still unknown. It has been hypothesized that, in MLC, the role of glial cells in brain ion homeostasis is altered in both physiological and inflammatory conditions. There is no therapy for MLC patients, only supportive treatment. As MLC2B patients show an MLC reversible phenotype, we speculated that the phenotype of MLC1 and MLC2A patients could also be mitigated by the re-introduction of the correct gene even at later stages. To prove this hypothesis, we injected in the cerebellar subarachnoid space of Mlc1 knockout mice an adeno-associated virus (AAV) coding for human MLC1 under the control of the glial-fibrillary acidic protein promoter. MLC1 expression in the cerebellum extremely reduced myelin vacuolation at all ages in a dose-dependent manner. This study could be considered as the first preclinical approach for MLC. We also suggest other potential therapeutic strategies in this review.This publication has 71 references indexed in Scilit:
- Megalencephalic Leukoencephalopathy with Subcortical Cysts Protein-1 (MLC1) Counteracts Astrocyte Activation in Response to Inflammatory SignalsMolecular Neurobiology, 2019
- Regulatory–auxiliary subunits of CLC chloride channel–transport proteinsJournal Of Physiology-London, 2015
- Functional Analyses of Mutations inHEPACAMCausing Megalencephalic LeukoencephalopathyHuman Mutation, 2014
- Megalencephalic leukoencephalopathy with subcortical cysts protein-1 modulates endosomal pH and protein trafficking in astrocytes: Relevance to MLC disease pathogenesisNeurobiology of Disease, 2014
- Expanding the spectrum of megalencephalic leukoencephalopathy with subcortical cysts in two patients with GLIALCAM mutationsneurogenetics, 2013
- The β1 subunit of the Na,K-ATPase pump interacts with megalencephalic leucoencephalopathy with subcortical cysts protein 1 (MLC1) in brain astrocytes: new insights into MLC pathogenesisHuman Molecular Genetics, 2010
- Biochemical characterization of MLC1 protein in astrocytes and its association with the dystrophin–glycoprotein complexMolecular and Cellular Neuroscience, 2008
- MLC1: A Novel Protein in Distal Astroglial ProcessesJournal of Neuropathology and Experimental Neurology, 2005
- Reversal of Pathology in the Entire Brain of Mucopolysaccharidosis Type VII Mice after Lentivirus-Mediated Gene TransferHuman Gene Therapy, 2000
- GFAP promoter directs astrocyte-specific expression in transgenic miceJournal of Neuroscience, 1994